Navigation Links
Amira Pharmaceuticals Announces Completion of Phase 1 Clinical Study for AM152, A Novel LPA1 Receptor Antagonist
Date:5/2/2011

SAN DIEGO, May 2, 2011 /PRNewswire/ -- Amira Pharmaceuticals, Inc. announced today initial positive data from a Phase 1 clinical study of AM152, the Company's oral selective antagonist of the LPA1 receptor.  Completion of this study positions Amira to initiate a Phase 2a study in patients suffering from systemic sclerosis, a systemic fibrotic disease, by early 2012.

"The Phase 1 clinical study in healthy volunteers demonstrated that AM152 is safe and well-tolerated at doses which are expected to provide a full range of receptor coverage in humans," said Isabelle DeArmond, Vice President, Clinical Development. "These results enable us to study AM152 at a wide range of doses in patients suffering from fibrotic diseases."

Bob Baltera, Chief Executive Officer, added, "Initiating a Phase 2a study in patients suffering from systemic sclerosis will be an important milestone for the team at Amira; we look forward to better understanding the potential therapeutic benefit of AM152."

AM152 is a novel LPA1 receptor antagonist developed by the scientists at Amira.  Preclinical data has demonstrated that antagonism of the LPA1 receptor inhibits fibrosis in several disease models.  Much of these data has been previously presented and published by Amira scientists and colleagues.  Amira Pharmaceuticals also recently announced that AM152 was granted Orphan Drug Status by the FDA for patients suffering from idiopathic pulmonary fibrosis (IPF).

About Amira

Founded in 2005 and headquartered in San Diego, Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory and fibrotic diseases.  Amira combines the rigor of a big pharmaceutical company with the ingenuity and energy of a small company, creating an environment for efficient development of novel compounds and effective pre-clinical and clinical program decisions.
'/>"/>

SOURCE Amira Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Amira Pharmaceuticals Receives Orphan Drug Status for a Novel LPA1 Antagonist, AM152, for the Treatment of Idiopathic Pulmonary Fibrosis
2. Amira Pharmaceuticals Announces the Nomination of an Orally Available Pre-Clinical Candidate in a New LPA-Related Program, an Autotaxin Inhibitor
3. Amira Pharmaceuticals Announces Initiation of Phase I Clinical Trial for AM152, A Novel LPA1 Antagonist
4. Amira Pharmaceuticals Announces IND Submission for Novel LPA1 Antagonist, AM152, for Potential Use in Fibrotic Diseases
5. Amira Pharmaceuticals Named One of Most Promising Biotech Companies by FierceBiotechs Annual Fierce 15
6. Visage Imaging Releases Amira 5.3
7. Amira Announces AM103 and AM803 Patent Grant in the United Kingdom
8. Amira Announces Second DP2 Antagonist Patent Grant in the United Kingdom
9. Anti-Fibrotic Data from Amira Pharmaceuticals LPA1 Receptor Antagonist Program Published in the British Journal of Pharmacology
10. Amira Pharmaceuticals Announces Efficacy of LPA1 Antagonist in a Preclinical Model of Scleroderma
11. Amira Pharmaceuticals Announces Initial Positive Phase 1 Clinical Data for AM461, A Back-Up to Amiras Lead DP2 Antagonist, AM211
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... , July 25, 2014  AMETEK, Inc. (NYSE: ... Kurtis L. Goos as Vice President and ... Interconnects and Packaging (EMIP) Division. "I am ... general management and business development experience, especially in the ... important contributions to the continued growth and success of ...
(Date:7/25/2014)... , July 25, 2014 Leading ... is returning for the seventh year to São Paulo, ... 7 th August 2014. The event will co-locate with ... most comprehensive meeting point for the pharmaceutical industry. ... top 25 countries for pharmaceutical sales are now exploring the ...
(Date:7/25/2014)... July 25, 2014  Arena Pharmaceuticals, Inc. (NASDAQ: ... corporate update and report second quarter 2014 financial results ... August 1, 2014. That same day, Arena will host ... Time (5:30 a.m. Pacific Time). The ... domestic callers and 914.495.8552 for international callers. Please specify ...
Breaking Medicine Technology:AMETEK Names Kurtis L. Goos, Vice President & General Manager, Engineered Medical Components 2CPhI South America 2014 Launches with Generics Showing Huge Growth 2CPhI South America 2014 Launches with Generics Showing Huge Growth 3CPhI South America 2014 Launches with Generics Showing Huge Growth 4Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 2Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 3
... Nov. 4 HeartWare International, Inc. (Nasdaq: HTWR ... less invasive, miniaturized circulatory support technologies revolutionizing the treatment ... in revenues to $7.5 million for the third quarter ... million in revenues in the second quarter ended June ...
... , THOUSAND OAKS, Calif., Nov. 4 Amgen (Nasdaq: ... applications for its 19th annual Amgen Award for Science ... recognize and honor extraordinary science teachers at the K-12 ... teaching and who achieve demonstrated results in student learning ...
Cached Medicine Technology:HeartWare International Reports Third Quarter Revenues of $7.5 Million 2HeartWare International Reports Third Quarter Revenues of $7.5 Million 3HeartWare International Reports Third Quarter Revenues of $7.5 Million 4HeartWare International Reports Third Quarter Revenues of $7.5 Million 5HeartWare International Reports Third Quarter Revenues of $7.5 Million 6HeartWare International Reports Third Quarter Revenues of $7.5 Million 7Call for Applications: The Amgen Award for Science Teaching Excellence 2Call for Applications: The Amgen Award for Science Teaching Excellence 3
(Date:7/25/2014)... NC (PRWEB) July 25, 2014 Researchers at ... the results of a study indicating that a man-made material ... mesothelioma among workers exposed to asbestos. Surviving Mesothelioma has just ... to read it now. , The French scientists ... developed mesothelioma between 1987 and 2006. One group of ...
(Date:7/25/2014)... 25, 2014 Healthpointe is proud ... clinic is offering Occupational Medicine services to the ... accepting referrals and workers’ compensation cases. , ... clinic include wound care treatment management, return-to-work and ... pre-employment screening & physicals, and illness and injury ...
(Date:7/25/2014)... the leading pan-European association representing medical oncology professionals, ... Data Protection Regulation [1] could make cancer research ... doctors and cancer patients. , The proposed wording ... patient consent, meaning that researchers would have to ... in order to consult their data or use ...
(Date:7/25/2014)... Yisrayl Hawkins, Pastor and Overseer of The House of Yahweh ... revealing to the whole world, including even the most devout ... in his new article. , Yisrayl says it all started ... by the Catholic Church. He says this plan included removing ... and replacing it with titles such as Lord and God. ...
(Date:7/25/2014)... According to the Addict Him To You Pdf ... guide that teaches women how to get the love of ... its review that this book consists of 4 parts, including:, ... won’t commit yet (and what to do about it) , ... ,     Part 3: How to touch his heart ...
Breaking Medicine News(10 mins):Health News:New Study Shows Mesothelioma Risk is Higher in Workers Exposed to Man-Made Insulator, According to Surviving Mesothelioma 2Health News:New Study Shows Mesothelioma Risk is Higher in Workers Exposed to Man-Made Insulator, According to Surviving Mesothelioma 3Health News:Healthpointe Offering Occupational Medicine Services in La Mirada 2Health News:Is Europe putting cancer research at risk? 2Health News:Yisrayl Hawkins Says You Have Been Tricked Into Worshipping Satan in New Article 2Health News:Addict Him To You Pdf Review Exposes Mirabelle Summers' Dating Guide – Vkool.com 2Health News:Addict Him To You Pdf Review Exposes Mirabelle Summers' Dating Guide – Vkool.com 3
... -- A program that helps elementary school students develop ... science and cultural studies may be one way to ... United States. In a new study, researchers assessed ... in which students explore, prepare and enjoy fresh, affordable ...
... 2011 A two-year study of patients in the ... (TAVR) in patients who have severe aortic stenosis and ... one-year findings and support the role of TAVR as ... today at the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) ...
... NOVEMBER 10, 2011 Results of the PARTNER ... replacement (TAVR) results in improved quality of life compared ... the transfemoral approach. The results of the study were ... (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation. ...
... thinking about Parkinson,s disease is that it,s a disorder of ... brain,s substantia nigra to die or become impaired. A study ... a hereditary form of Parkinson,s disease cause mitochondria to run ... to stop them. Findings appear in the November 11 issue ...
... physicians for increasing the volume of visits and procedures ... health outcomes," the American College of Physicians (ACP) today ... Pensions (HELP) in a hearing on Improving Quality, Lowering ... does not provide incentives for physicians to coordinate care; ...
... News) -- All the color variations seen in prehistoric ... populations, which indicates that the ancient human artists accurately ... The research is also the first to provide ... Previous DNA studies produced evidence only for bay (reddish ...
Cached Medicine News:Health News:Cooking Class Benefits Kids in Many Ways 2Health News:Results of the PARTNER Trial Cohort B 2-year follow up presented at TCT 2011 2Health News:Quality of life benefits of transcatheter aortic valve replacement differ by access site 2Health News:Why do neurons die in Parkinson's disease? 2Health News:Internists express strong support for ACA's programs to support coordinated care 2Health News:Cave Art Accurately Depicted Horses of Different Colors 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: